Mitra Tavakkoli
Vice President, Clinical Development & Head of Drug Safety Sangamo Therapeutics
Seminars
Thursday 26th March 2026
Panel Discussion: Connecting with Communities to Build Trust in Clinical Research
1:30 pm
- Building trust through transparent education that supports long-term trial participation
- Translating complex gene therapy concepts into clear, accessible materials for families and caregivers
- Sharing real-world strategies that improve recruitment, retention, and patient satisfaction
Thursday 26th March 2026
Isaralgagene civaparvovec (ST-920) shows positive mean annualized eGFR slope in adults with Fabry disease: Topline results from the registrational Phase 1/2 STAAR gene therapy study and long-term follow-up study
12:05 pm
- Totality of data supports potential for ST-920 as a one-time, durable treatment of underlying pathology of Fabry disease to provide meaningful, multi-organ, clinical benefits above current standards of care
- ST-920 has potential as a one-time, durable treatment option for Fabry disease that can improve patient outcomes
